Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: Retrospective analysis of 58 prescription-event monitoring cohort studies
Autore:
Martin, RM; Wilton, LV; Mann, RD;
Indirizzi:
Drug Safety Res Unit, Southampton SO31 1AA, Hants, England Drug Safety ResUnit Southampton Hants England SO31 1AA A, Hants, England Univants,hampton, Sch Med, Fac Med Hlth & Biol Sci, Southampton SO16 7PX, H Univ Southampton Southampton Hants England SO16 7PX uthampton SO16 7PX, H
Titolo Testata:
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
fascicolo: 3, volume: 8, anno: 1999,
pagine: 179 - 189
SICI:
1053-8569(199905/06)8:3<179:POCSVE>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALLERGIC GRANULOMATOSIS; SYSTEMIC VASCULITIS; ANGIITIS; CLASSIFICATION; EPIDEMIOLOGY; THERAPY; ASTHMA;
Keywords:
Churg-Strauss syndrome; vasculitis; eosinophilia; prescription-event monitoring; post-marketing surveillance; prevalence study; asthma; leukotriene receptor antagonists; pharmacoepidemiology; pharmacovigilance;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Martin, RM Drugnts,ety Res Unit, Bursledon Hall,Blunden Lane, Southampton SO31 1AA, Ha Drug Safety Res Unit Bursledon Hall,Blunden Lane Southampton Hants England SO31 1AA
Citazione:
R.M. Martin et al., "Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: Retrospective analysis of 58 prescription-event monitoring cohort studies", PHARMA D S, 8(3), 1999, pp. 179-189

Abstract

Purpose - Churg-Strauss syndrome is characterised by hypsreosinophilia, systemic vasculitis and asthma. The cause is usually unknown, but there have been reports of an association with particular drugs, including anti-asthmadrugs. Our aim was to estimate the prevalence of Churg-Strauss syndrome and related conditions in post-marketing safety studies of new anti-asthma drugs. Methods - We accessed the prescription-event monitoring (PEM) database of the Drug Safety Research Unit (DSRU). This database currently has information on 622 294 patients observed during 58 completed PEM studies of individual drugs, including 35 799 patients in studies of new anti-asthma drugs. Results - Overall, four cases of Churg-Strauss syndrome were identified during these studies, giving a period prevalence rate of 6.8 (95% confidence limits [CL]: 1.8 17.3) per million patient-years of observation. The periodprevalence of Churg-Strauss syndrome was significantly greater in the PEM cohorts of anti-asthma drugs (63.4 million patient-years of observation: 95% CL: 13.3-188.1), than the other PEM drug cohorts (1.8 per million patient-years of observation; 95% CE: 0.05-10.2) (rate ratio: 35.1; 95% CL: 2.8-1839.9; p = 0.002). Conclusion - Our data provide estimates of the prevalence of Churg-Strausssyndrome and related conditions in cohorts of asthmatic patients, which may be useful during the pharmacovigilance of new asthma drugs, including thenew leukotriene receptor antagonists. Copyright (C) 1999 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 19:23:01